{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:33:01Z","timestamp":1775583181892,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010377","name":"National Institute for Health and Care Excellence","doi-asserted-by":"publisher","award":["Health Technology Assessment Programme"],"award-info":[{"award-number":["Health Technology Assessment Programme"]}],"id":[{"id":"10.13039\/100010377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001721","name":"University of Groningen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40273-020-00971-x","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T01:02:58Z","timestamp":1604451778000},"page":"171-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"39","author":[{"given":"Willem J. A.","family":"Witlox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine E.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Riemsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa Huertas","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Posadzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Worthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier G. L. V.","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram L. T.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"Kleijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela A.","family":"Joore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-9906","authenticated-orcid":false,"given":"Antoinette D. I.","family":"van Asselt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"971_CR1","unstructured":"Riemsma R, Van Asselt ADI, Witlox W, Huertas Carrera V, Posadzki P, Armstrong N, et al. Lenalidomide with rituximab for previously treated follicular lymphoma and marginal zone lymphoma: a Single Technology Assessment. York: Kleijnen Systematic Reviews Ltd, 2019. https:\/\/www.nice.org.uk\/guidance\/ta627\/evidence. Accessed 7 Jul 2020."},{"key":"971_CR2","unstructured":"National Institute for Health and Care Excellence. Lenalidomide with rituximab for previously treated follicular lymphoma and marginal zone lymphoma. Final scope. London: National Institute for Health and Care Excellence, 2019. https:\/\/www.nice.org.uk\/guidance\/gid-ta10323\/documents\/final-scope. Accessed 25 May 2019."},{"key":"971_CR3","unstructured":"Celgene Ltd. Lenalidomide for treated follicular lymphoma and marginal zone lymphoma [ID1374]. Response to request for clarification from the ERG. August 2019. Celgene Ltd, 2019."},{"issue":"14","key":"971_CR4","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188\u201399.","journal-title":"J Clin Oncol"},{"issue":"10","key":"971_CR5","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295\u2013301.","journal-title":"Blood"},{"issue":"8","key":"971_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081\u201393.","journal-title":"Lancet Oncol."},{"key":"971_CR7","unstructured":"Haematological Malignancy Research Network (HMRN). Clinical management and outcome of follicular lymphoma (FL) with a focus on relapsed\/refractory disease (draft report). 17 July 2019. Haematological Malignancy Research Network, 2019."},{"key":"971_CR8","unstructured":"National Institute for Health and Care Excellence. Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab. NICE technology appraisal guidance 472. London: National Institute for Health and Care Excellence, 2017. https:\/\/www.nice.org.uk\/guidance\/ta472. Accessed 25 May 2019."},{"key":"971_CR9","unstructured":"National Institute for Health and Care Excellence. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin\u2019s lymphoma. NICE technology appraisal guidance 137. London: National Institute for Health and Care Excellence, 2008. https:\/\/www.nice.org.uk\/guidance\/ta137. Accessed 1 Feb 2019."},{"issue":"6","key":"971_CR10","doi-asserted-by":"publisher","first-page":"A294","DOI":"10.1016\/S1098-3015(10)63491-2","volume":"9","author":"D Wild","year":"2006","unstructured":"Wild D, Walker M, Pettengell R, Lewis G. Pcn62 utility elicitation in patients with follicular lymphoma. Value Health. 2006;9(6):A294.","journal-title":"Value Health."},{"key":"971_CR11","unstructured":"NHS Improvement. NHS reference costs 2017\/18. London: NHS Improvement, 2018. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. Accessed 26 Apr 2019."},{"key":"971_CR12","unstructured":"Personal Social Services Research Unit. Unit costs of health and social care 2018. Canterbury: University of Kent, 2018. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2018\/. Accessed 25 Jul 2019."},{"key":"971_CR13","unstructured":"MIMS. Monthly Index of Medical Specialities (MIMS) Online. 2020. Available from: https:\/\/www.mims.co.uk\/. Accessed 7 Jul 2020."},{"key":"971_CR14","unstructured":"GOV.UK. Drugs and pharmaceutical electronic market information tool (eMIT). 2019. Available from: https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit. Accessed 25 Apr 2019."},{"key":"971_CR15","unstructured":"National Institute for Health and Care Excellence. Obinutuzumab for untreated advanced follicular lymphoma. NICE technology appraisal guidance 513. London: National Institute for Health and Care Excellence, 2018. https:\/\/www.nice.org.uk\/guidance\/ta513. Accessed 5 Jan 2019."},{"key":"971_CR16","unstructured":"National Institute for Health and Care Excellence. Rituximab for the first-line treatment of stage III-IV follicular lymphoma. NICE technology appraisal guidance 243. London: National Institute for Health and Care Excellence, 2012. https:\/\/www.nice.org.uk\/guidance\/ta243. Accessed 26 Apr 2019."},{"key":"971_CR17","unstructured":"Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. Sheffield: NICE Decision Support Unit, 2017. http:\/\/www.nicedsu.org.uk. Accessed 28 May 2019."},{"key":"971_CR18","unstructured":"Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluaions alongside clinical trials - extrapolation with patient-level data [Internet]. Sheffield: NICE Decision Support Unit, 2011. http:\/\/www.nicedsu.org.uk. Accessed 10 May 2019."},{"key":"971_CR19","doi-asserted-by":"crossref","unstructured":"Pereira C, Negreiro F, Silva C. PSY43 Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal. Value Health 2010;13(7):A468.","DOI":"10.1016\/S1098-3015(11)72992-8"},{"key":"971_CR20","unstructured":"Celgene Ltd. Lenalidomide with rituximab for treated follicular lymphoma and marginal zone lymphoma [ID1374]. Addendum for the amended follicular lymphoma only population. Company evidence submission to National Institute for Health and Care Excellence. Single Technology Appraisal (STA). Celgene Ltd, 2019."},{"issue":"4","key":"971_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40273-019-00870-w","volume":"38","author":"WJA Witlox","year":"2020","unstructured":"Witlox WJA, van Asselt ADI, Wolff R, Armstrong N, Worthy G, Chalker A, et al. Durvalumab for the treatment of locally advanced, unresectable, stage III non-small cell lung cancer: an Evidence Review Group perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2020;38(4):317\u201324.","journal-title":"Pharmacoeconomics."},{"issue":"10","key":"971_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s40273-019-00792-7","volume":"37","author":"SE Grimm","year":"2019","unstructured":"Grimm SE, Fayter D, Ramaekers BLT, Petersohn S, Riemsma R, Armstrong N, et al. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: an Evidence Review Group perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2019;37(10):1195\u2013207.","journal-title":"Pharmacoeconomics."},{"issue":"2","key":"971_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00971-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-020-00971-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-020-00971-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:43:32Z","timestamp":1612835012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-020-00971-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["971"],"URL":"https:\/\/doi.org\/10.1007\/s40273-020-00971-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"15 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme. Please visit the HTA programme website for further project information ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"WW, RR, NA, SR, SD, VHC, PP, GW, XP, BR, JK, MJ, SG, and AvA have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors have commented on the submitted manuscript and have given their approval for the final version to be published. RR, SD, and JK critiqued the clinical effectiveness data reported by the company. VHC and PP critiqued the literature searches undertaken by the company. GW critiqued the statistical analyses performed by the company. WW, NA, SR, XP, BR, MJ, SG, and AvA critiqued the mathematical model provided and the cost-effectiveness analyses submitted by the company. AvA acts as overall guarantor for this article. This article has not been externally peer reviewed by <i>PharmacoEconomics<\/i>.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}